Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or Remission
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.
PURPOSE: This laboratory study is looking at resistance to methotrexate in patients with acute lymphoblastic leukemia in relapse or remission.
Genetic: microarray analysis
Genetic: reverse transcriptase-polymerase chain reaction
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||A Study of the Mechanisms of Intrinsic and Acquired Methotrexate Resistance in Acute Lymphocytic Leukemia|
- Mechanisms of intrinsic and acquired methotrexate resistance
- Correlation of acquired methotrexate resistance with dosage or timing of methotrexate administration
- Correlation of acquired methotrexate resistance with other clinical factors
|Study Start Date:||June 1998|
|Study Completion Date:||April 2006|
|Primary Completion Date:||March 2005 (Final data collection date for primary outcome measure)|
- Determine the mechanisms of intrinsic and acquired methotrexate resistance using in vitro assays of matched initial diagnosis, relapsed, and nonrelapsed (control) leukemic blast samples from patients with acute lymphoblastic leukemia in relapse or remission.
- Determine if the mechanisms of acquired methotrexate resistance are related to dosage or timing of methotrexate administration or other clinical factors in these patients.
OUTLINE: Random samples of frozen leukemic blasts from relapsing patients at initial diagnosis and relapse are selected. A corresponding sample from nonrelapsing patients (control) at initial diagnosis is also randomly selected.
Reduced folate carrier (RFC) and dehydrofolate reductase (DHFR) expression is measured using a quantitative reverse transcriptase-polymerase chain reaction assay of prepared RNA. DHFR gene amplification is measured by a dot blot analysis of prepared DNA. Results of these assays are used to determine if a particular mechanism of acquired methotrexate resistance is associated with a particular subset of acute lymphoblastic leukemia patients. Data are collected regarding the actual timing and dosage of methotrexate received by each patient and are correlated with the mechanisms of resistance.
PROJECTED ACCRUAL: A total of 135 paired samples will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00899899
|Study Chair:||Richard Gorlick, MD||Children's Hospital at Montefiore|